Value Proposition Development and HEOR Strategy for Belzutifan in Renal Cell Carcinoma

Authors

Olivia Reily, Thomas Jefferson UniversityFollow

Document Type

Presentation

Publication Date

7-24-2024

Comments

Presentation: 19:21

Abstract

Renal Cell Carcinoma (RCC) associated with von Hippel-Lindau (VHL) syndrome affects roughly 3000 patients within the United States and has limited treatment options with one treatment, belzutifan, being new to the market. This study aimed to develop a value proposition plan for belzutifan from the perspective of an industry-based US Health Economics and Outcomes Research (HEOR) team to summarize the clinical and economic evidence for payers. A literature search was conducted utilizing key words belzutifan, RCC and VHL syndrome to identify existing evidence on belzutifan and identify missing evidence to determine additional studies needed to complete the dossier. The current evidence supports the clinical efficacy of belzutifan but not its cost-effectiveness, with an unfavorable ICER per QALY. As such, more research would be needed to corroborate its value proposition. Among potential studies, a budget impact analysis (BIA) was deemed critical to present information to payers. This BIA would need to consider the budget variation while adding belzutifan to the current competitor, everolimus, on a drug formulary from a payer perspective. A step-by-step methodology was identified to build this BIA. As belzutifan was shown to be efficacious but not necessarily cost-effective to treat RCC patients with VHL syndrome, the results of this capstone highlight the importance of generating robust HEOR evidence to strengthen its value proposition to payers and healthcare plans.

Recommended Citation

Language

English